Live birth or ongoing pregnancy · assisted reproduction technology cycles
Summary of findings table ‐ Progestagen showed no clear difference in live birth or ongoing pregnancy compared with gnRH agonist (low certainty).
1 finding from 1 review
Clinical pregnancy · assisted reproduction technology cycles
Summary of findings table ‐ Progestagen showed no clear difference in clinical Pregnancy compared with gnRH agonist (low certainty).
1 finding from 1 review
Clinical pregnancy · assisted reproduction technology cycles
Summary of findings table ‐ Progestogen 1 showed no clear difference in clinical pregnancy ‐ Normo‐responders (MPA 10 mg versus… compared with progestogen 2 (moderate certainty).
1 finding from 1 review
Live birth or ongoing pregnancy ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in live birth or ongoing pregnancy ‐ Poor‐responders (MPA 10 mg versus… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Cumulative pregnancy rate · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in proven catheter‐related bloodstream infection (CRBSI) expressed by… compared with PI (low certainty).
1 finding from 1 review
Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
CHG‐IPA showed no clear difference in premature central line removal, defined as number of central venous… compared with CHG‐A (moderate certainty).
1 finding from 1 review
Central line‐associated bloodstream infection (CLABSI) expressed using absolute rates of infants · neonates that require central line
It is very uncertain whether CHG‐IPA changes central line‐associated bloodstream infection (CLABSI) expressed… compared with PI (very low certainty).
1 finding from 1 review
Premature central line removal, defined as number of central venous catheters (CVC) removed in the trial as deemed by the author as the source of infection (premature central line removal) · neonates that require central line
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proven catheter‐related bloodstream infection (CRBSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in proven catheter‐related bloodstream infection (CRBSI) expressed by… compared with CHG‐A (low certainty).
1 finding from 1 review
Central‐line associated bloodstream infection (CLABSI) expressed by the authors of the individual trial as absolute rates · neonates that require central line
CHG‐IPA showed no clear difference in central‐line associated bloodstream infection (CLABSI) expressed by… compared with CHG‐A (low certainty).
1 finding from 1 review
Response to treatment at 8 weeks · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher response to treatment at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Acceptability ‐ total dropouts · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to any cause at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects (dropouts) · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher number of dropouts due to adverse effects at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Remission · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole leads to higher remission rates at 8 weeks compared with antidepressive agents (high certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: akathisia (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Weight gain · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Positive‐pressure ventilation after institution of treatment · treatment of apnea
It is very uncertain whether doxapram changes 2a. Need for positive pressure ventilation after initiation of… compared with no treatment, placebo, methylxanthine (including theophylline,… (very low certainty).
3 findings from 1 review
Treatment failure · preterm infants receiving nasal CPAP
Bubble may leads to lower treatment failure compared with ventilator or Infant Flow Driver nasal continuous positive airway… (low certainty).
1 finding from 1 review